Regulators have published results from a six-year international active pharmaceutical ingredient inspection programme that Johnson Matthey says benefits companies and authorities.
Entire clinical research model at risk: ‘Call to action has to be now,’ says PRA
from Outsourcing-Pharma.com
Shire sells cancer biz for $2.4bn
from BioPharma-Reporter.com
Pall and Artesyn Biosolutions team to industrialize single-use tech
from BioPharma-Reporter.com
Marken adding nursing network for at-home clinical trials
from Outsourcing-Pharma.com
GSK offloads gene therapy portfolio and takes stake in Orchard
Mergers and acquisitions
CMO for Pfizer ADHD drug hit with US FDA warning
Lifecycle management
Novartis upping presence in gene therapies through $8.7bn AveXis buy
Mergers and acquisitions
Plant issues plague Celltrion and Teva as FDA issues two biosimilars CRLs
Lifecycle management
